China Aoxing Pharmaceutical Company Acquires a Novel Menstrual Pain Drug
May 14 2009 - 7:00AM
Marketwired
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China
Aoxing"), a pharmaceutical company specializing in research,
development, manufacturing and marketing of narcotic and
pain-management products, today announced that it has acquired all
rights to TJSL, a novel drug at Phase II development stage to treat
primary dysmenorrhea ("PD"), or menstrual pain, in adult women.
The prevalence rates of PD among women are from 60 to 90
percent. It is estimated that 64% of women in China purchase
menstrual pain drugs on regular basis. The market size of
healthcare product to address menstrual pain is estimated at $3
billion per year in China.
TJSL is a capsule form of selected herbal medicines at Phase II
clinical development under the protocol approved by the China State
Food and Drug Administration ("SFDA"). The mechanism of action of
the drug deserves further investigation, but appears to be its
capability of reversing the effects of endometrial prostaglandin,
reducing the frequency and strength of uterine contraction as well
as providing pain relief, based on in vivo study.
The ongoing Phase II clinical study is a multi-center,
randomized, double-blind and placebo-controlled trial of over 200
female patients under three month oral therapy at four academic
hospitals in China. The endpoint of the studies is the drug's
efficacy and safety, including improvement of abdominal pain during
menstruation, measured by visual analogue scale ("VAS"). The study
has progressed well and already moved into post-treatment
observation stage for its enrolled patients between 18 and 35 years
old. The Phase II clinical study is expected to be completed in
second half of 2009.
"China Aoxing has made the strategic decision to expand our
commitment within the field of pain management," stated Juan Yue
Han, Chairman and the CEO of China Aoxing. "The acquisition of TJSL
product significantly enhances our profile within the women health
community while enabling us to serve yet another greatly
underserved market segment in pain management."
"Based on the progress and results to date, TJSL appears to be
very promising for routine treatment of PD. A large body of
evidence has indicated the drug's efficacy and safety empirically
collected from the treatment of over 800 patients who suffered from
PD. We look forward to additional supporting data from the ongoing
trial with over 200 patients, which we believe to be the most
comprehensive and robust Phase II study for PD indication in
China," commented Ms. Liying Yang, the Vice President of Research
& Development in China Aoxing.
About Primary Dysmenorrhea ("PD")
Primary dysmenorrhea is defined as recurrent, cramping pain in
the lower abdomen occurring just before or during menstruation, in
the absence of demonstrable pelvic disease, such as endometriosis.
Prevalence rates are as high as 90 percent. Initial presentation of
PD typically occurs in adolescence. It is a common cause of
absenteeism and reduced quality of life in women. Women with PD
have increased production of endometrial prostaglandin, resulting
in increased uterine tone and stronger, more frequent uterine
contractions.
Pharmacological interventions available in the market include
non-steroidal anti-inflammatory drugs (NSAIDs), hormomal
contraceptives, levonorgestrel intrauterine contraception and
tocolytics.
About TJSL Capsules
TJSL was originated by Professor X. Tian, a well-known
gynecologist in China. The drug is composed of several herbal
medicines optimized based on her 40 years of medical research in
treating PD. The drug has been used empirically by over 800
patients who suffered from PD. From in vivo studies, the drug was
capable of reversing the effects of endometrial prostaglandin,
reducing the frequency and strength of uterine contraction as well
as providing pain relief.
About China Aoxing Pharmaceutical Company, Inc.
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a
pharmaceutical company located in China specializing in research,
development, manufacturing and distribution of a variety of
narcotics and pain-management products. It has a strategic alliance
with American Oriental Bioengineering, Inc. (NYSE: AOB) to develop
and market various narcotic drugs in China. Headquartered in
Shijiazhuang City, the pharmaceutical capital of China, outside of
Beijing, China Aoxing has China's largest and the most advanced
manufacturing facility for highly regulated narcotic medicines,
addressing a very under-served and fast-growing market in China.
Its facility is one of the few GMP facilities licensed for
narcotics medicines. The Company is working closely with the
Chinese government and SFDA to assure the strictly regulated
availability to medical professionals of its narcotic drugs and
pain medicines throughout China.
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks and
uncertainties that may cause actual results to differ materially
from those set forth in these statements. The economic,
competitive, governmental, technological and other risk factors
identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-KSB for the year ended
June 30, 2008, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
Contact: Wei Zhang Investor Relations China Aoxing
Pharmaceutical Company, Inc Email: chinaaoxing@gmail.com Telephone:
646 - 512 - 5662
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024